Huperzine A
Huperzine A (from Huperzia serrata)
A potent natural acetylcholinesterase inhibitor that enhances memory, focus, and cognitive function.
Huperzine A is a naturally occurring compound from Chinese club moss (Huperzia serrata) that has been used in Chinese medicine for centuries. It works by inhibiting acetylcholinesterase, the enzyme that breaks down acetylcholine, thereby increasing levels of this crucial memory and learning neurotransmitter. It's used for cognitive enhancement and is studied for Alzheimer's disease.
Mechanisms of Action
Acetylcholinesterase Inhibition
Blocks the enzyme that breaks down acetylcholine
Neuroprotection
Protects neurons from damage
Neurogenesis Support
May promote new brain cell growth
Recommended Dose
50-200mcg twice daily
Loading: Start with 50mcg to assess tolerance
Optimal Timing
- Morning and early afternoon
- Avoid evening (may cause vivid dreams)
Can be taken without food
Best Form
Huperzine A capsules (standardized extract)
Alternatives: Huperzia serrata extract
Very potent - measured in micrograms (mcg), not milligrams. Ensure accurate dosing.
Duration
Minimum: 2 weeks
Optimal: 4 weeks
Cycling: Use for 2-4 weeks, then take 1-2 weeks off to prevent tolerance and receptor downregulation
Note: Due to its long half-life (~10 hours), cycling is recommended to prevent tolerance and accumulation.
Personalized Dosage Calculator
Get a dosage recommendation tailored to your body weight, age, goals, and health profile.
Set up your health profile for personalized recommendations
Enhanced Memory
Improved memory formation and recall
Improved Focus
Better concentration and attention
Enhanced Learning
Faster acquisition of new information
Vivid Dreams
May cause intense dreams
Studied for this population; consult doctor
Who Should NOT Take This
- Heart conditions (can slow heart rate)
- Asthma/COPD (can increase bronchial secretions)
- GI ulcers (increases gastric acid)
Drug Interactions
Additive effects - do not combine
Opposing effects - may reduce effectiveness of either
Possible Side Effects
Tip: Reduce dose; take with food
Tip: Avoid evening dosing
Tip: Reduce dose
Warnings
- Must cycle to prevent tolerance
- Do not combine with prescription cholinesterase inhibitors
- Avoid if you have heart rhythm issues
Top studies from 40+ peer-reviewed papers
Perng CH et al. • Psychopharmacology (2018)
“The most effective intervention for dementia available is symptomatic treatment for vascular dementia.”
Key Findings:
- The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
- The most effective intervention for dementia available is symptomatic treatment for vascular dementia.
- Antipsychotic treatment for dementia alleviates cognitive dysfunction less effectively than does symptomatic treatment.
- Alternative therapies are also effective at present.
Chan ES et al. • The Cochrane database of systematic reviews (2018)
“We found moderate- to very low-quality evidence of benefit and harm of TCHMs for VaD.”
Key Findings:
- Two TCHMs (NaoMaiTai and TongXinLuo) had a 5% or more increased risk of AEs compared to the 'no Treatment' control, but the quality of this evidence was poor.
- We found moderate- to very low-quality evidence of benefit and harm of TCHMs for VaD.
- Methodological inadequacies need to be addressed by better conducted and reported trials.
- We identified NaoMaiTai, NaoXinTong and TongXinLuo as warranting special research priority.
Laver K et al. • BMJ open (2016)
“Healthcare professionals should ensure that people with dementia are encouraged to exercise and that primary carers are trained and supported to provide safe and effective care for the person with dementia.”
Key Findings:
- The quality of the reviews varied; however most (65%) scored 8/11 or more on the AMSTAR tool, indicating high quality.
- Healthcare professionals should ensure that people with dementia are encouraged to exercise and that primary carers are trained and supported to provide safe and effective care for the person with dementia.
- Acetylcholinesterase inhibitors or memantine should be trialled unless contraindicated.
Yang G et al. • PloS one (2013)
“Huperzine A appears to have beneficial effects on improvement of cognitive function, daily living activity, and global clinical assessment in participants with Alzheimer's disease.”
Key Findings:
- Huperzine A appears to have beneficial effects on improvement of cognitive function, daily living activity, and global clinical assessment in participants with Alzheimer's disease.
- However, the findings should be interpreted with caution due to the poor methodological quality of the included trials.
- Further research warranted to confirm findings
Yue J et al. • The Cochrane database of systematic reviews (2012)
“The currently available evidence is insufficient to assess the potential for huperzine A in the treatment of MCI.”
Key Findings:
- The currently available evidence is insufficient to assess the potential for huperzine A in the treatment of MCI.
- Randomised double-blind placebo-controlled trials are needed.
- Further research warranted to confirm findings
Study Type Distribution
Goals This Supplement Supports
Related Goals
This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.